SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on October 3, 2002; DOI 10.1182/blood-2002-05-1459. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-05-1459v1 101/3/837    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Barjesteh van Waalwijk van Doorn-Khosrovani, S. Articles by Delwel, R. Search for Related Content PubMed PubMed Citation Articles by Barjesteh van Waalwijk van Doorn-Khosrovani, S. Articles by Delwel, R. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 February 2003, Vol. 101, No. 3, pp. 837-845 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Claudia Erpelinck, Wim L. J. van Putten, Peter J. M. Valk, Sonja van der Poel-van de Luytgaarde, Ronald Hack, Rosalyn Slater, Elisabeth M. E. Smit, H. Berna Beverloo, Gregor Verhoef, Leo F. Verdonck, Gert J. Ossenkoppele, Pieter Sonneveld, Georgine E. de Greef, Bob Löwenberg, and Ruud Delwel From the Institute of Hematology, Erasmus Medical Centre, Rotterdam, Netherlands; the Department of Cell Biology and Genetics, Erasmus Medical Centre, Rotterdam, Netherlands; the Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, Netherlands; the Department of Hematology, Vrije Universiteit Medical Centre, Amsterdam, Netherlands; the Department of Hematology, University Medical Centre, Utrecht, Netherlands; and the Department of Hematology, University Hospitals, Katholieke Universiteit Leuven, Leuven, Belgium. The proto-oncogene EVI1 encodes a DNA binding protein and is located on chromosome 3q26. The gene is aberrantly expressed in acute myeloid leukemia (AML) patients carrying 3q26 abnormalities. Two mRNAs are transcribed from this locus: EVI1 and a fusion of EVI1 with MDS1 (MDS1-EVI1), a gene located 5' of EVI1. The purpose of this study was to investigate which of the 2 gene products is involved in transformation in human AML. To discriminate between EVI1 and MDS1-EVI1 transcripts, distinct real-time quantitative polymerase chain reaction (PCR) assays were developed. Patients with 3q26 abnormalities often showed high EVI1 and MDS1-EVI1 expression. In a cohort of 319 AML patients, 4 subgroups could be distinguished: EVI1+ and MDS1-EVI1 (6 patients; group I), EVI1+ and MDS1-EVI1+ (26 patients; group II), EVI1 and MDS1-EVI1+ (12 patients; group III), and EVI1 and MDS1-EVI1 (275 patients; group IV). The only 4 patients with a 3q26 aberration belonged to groups I and II. Interestingly, high EVI1 and not MDS1-EVI1 expression was associated with unfavorable karyotypes (eg, 7/7q) or complex karyotypes. Moreover, a significant correlation was observed between EVI1 expression and 11q23 aberrations (mixed lineage leukemia [MLL] gene involvement). Patients from groups I and II had significantly shorter overall and event-free survival than patients in groups III and IV. Our data demonstrate that high EVI1 expression is an independent poor prognostic marker within the intermediate- risk karyotypic group. © 2003 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. H. Metzeler, A. Dufour, T. Benthaus, M. Hummel, M.-C. Sauerland, A. Heinecke, W. E. Berdel, T. Buchner, B. Wormann, U. Mansmann, et al. ERG Expression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis of ERG, MN1, and BAALC Transcript Levels Using Oligonucleotide Microarrays J. Clin. Oncol., October 20, 2009; 27(30): 5031 - 5038. [Abstract] [Full Text] [PDF] C. M. Santamaria, M. C. Chillon, R. Garcia-Sanz, C. Perez, M. D. Caballero, F. Ramos, A. G. de Coca, J. M. Alonso, P. Giraldo, T. Bernal, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia Blood, July 2, 2009; 114(1): 148 - 152. [Abstract] [Full Text] [PDF] L. Laricchia-Robbio, K. Premanand, C. R. Rinaldi, and G. Nucifora EVI1 Impairs Myelopoiesis by Deregulation of PU.1 Function Cancer Res., February 15, 2009; 69(4): 1633 - 1642. [Abstract] [Full Text] [PDF] B. Lowenberg Diagnosis and Prognosis in Acute Myeloid Leukemia -- The Art of Distinction N. Engl. J. Med., May 1, 2008; 358(18): 1960 - 1962. [Full Text] [PDF] S. Lugthart, E. van Drunen, Y. van Norden, A. van Hoven, C. A. J. Erpelinck, P. J. M. Valk, H. B. Beverloo, B. Lowenberg, and R. Delwel High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated Blood, April 15, 2008; 111(8): 4329 - 4337. [Abstract] [Full Text] [PDF] B. Lowenberg Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety Hematology, January 1, 2008; 2008(1): 1 - 11. [Abstract] [Full Text] [PDF] H. Hasle, T. A. Alonzo, A. Auvrignon, C. Behar, M. Chang, U. Creutzig, A. Fischer, E. Forestier, A. Fynn, O. A. Haas, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study Blood, June 1, 2007; 109(11): 4641 - 4647. [Abstract] [Full Text] [PDF] M. Nanjundan, Y. Nakayama, K. W. Cheng, J. Lahad, J. Liu, K. Lu, W.-L. Kuo, K. Smith-McCune, D. Fishman, J. W. Gray, et al. Amplification of MDS1/EVI1 and EVI1, Located in the 3q26.2 Amplicon, Is Associated with Favorable Patient Prognosis in Ovarian Cancer Cancer Res., April 1, 2007; 67(7): 3074 - 3084. [Abstract] [Full Text] [PDF] K. Mrozek, G. Marcucci, P. Paschka, S. P. Whitman, and C. D. Bloomfield Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood, January 15, 2007; 109(2): 431 - 448. [Abstract] [Full Text] [PDF] H. Dohner Implication of the Molecular Characterization of Acute Myeloid Leukemia Hematology, January 1, 2007; 2007(1): 412 - 419. [Abstract] [Full Text] [PDF] C. E. Dunbar The Yin and Yang of Stem Cell Gene Therapy: Insights into Hematopoiesis, Leukemogenesis, and Gene Therapy Safety Hematology, January 1, 2007; 2007(1): 460 - 465. [Abstract] [Full Text] [PDF] M. Heuser, G. Beutel, J. Krauter, K. Dohner, N. von Neuhoff, B. Schlegelberger, and A. Ganser High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics Blood, December 1, 2006; 108(12): 3898 - 3905. [Abstract] [Full Text] [PDF] L. Laricchia-Robbio, R. Fazzina, D. Li, C. R. Rinaldi, K. K. Sinha, S. Chakraborty, and G. Nucifora Point Mutations in Two EVI1 Zn Fingers Abolish EVI1-GATA1 Interaction and Allow Erythroid Differentiation of Murine Bone Marrow Cells Mol. Cell. Biol., October 15, 2006; 26(20): 7658 - 7666. [Abstract] [Full Text] [PDF] M. D. Radmacher, G. Marcucci, A. S. Ruppert, K. Mrozek, S. P. Whitman, J. W. Vardiman, P. Paschka, T. Vukosavljevic, C. D. Baldus, J. E. Kolitz, et al. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study Blood, September 1, 2006; 108(5): 1677 - 1683. [Abstract] [Full Text] [PDF] C. S. Wilson, G. S. Davidson, S. B. Martin, E. Andries, J. Potter, R. Harvey, K. Ar, Y. Xu, K. J. Kopecky, D. P. Ankerst, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction Blood, July 15, 2006; 108(2): 685 - 696. [Abstract] [Full Text] [PDF] C. D. Baldus, C. Thiede, S. Soucek, C. D. Bloomfield, E. Thiel, and G. Ehninger BAALC Expression and FLT3 Internal Tandem Duplication Mutations in Acute Myeloid Leukemia Patients With Normal Cytogenetics: Prognostic Implications J. Clin. Oncol., February 10, 2006; 24(5): 790 - 797. [Abstract] [Full Text] [PDF] R. G. W. Verhaak, C. S. Goudswaard, W. van Putten, M. A. Bijl, M. A. Sanders, W. Hugens, A. G. Uitterlinden, C. A. J. Erpelinck, R. Delwel, B. Lowenberg, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance Blood, December 1, 2005; 106(12): 3747 - 3754. [Abstract] [Full Text] [PDF] B. Calmels, C. Ferguson, M. O. Laukkanen, R. Adler, M. Faulhaber, H.-J. Kim, S. Sellers, P. Hematti, M. Schmidt, C. von Kalle, et al. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells Blood, October 1, 2005; 106(7): 2530 - 2533. [Abstract] [Full Text] [PDF] L. Bullinger and P. J.M. Valk Gene Expression Profiling in Acute Myeloid Leukemia J. Clin. Oncol., September 10, 2005; 23(26): 6296 - 6305. [Abstract] [Full Text] [PDF] M. S. Tallman, D. G. Gilliland, and J. M. Rowe Drug therapy for acute myeloid leukemia Blood, August 15, 2005; 106(4): 1154 - 1163. [Abstract] [Full Text] [PDF] K. N. Bhalla Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993. [Abstract] [Full Text] [PDF] S. F. Landrette, Y.-H. Kuo, K. Hensen, S. B. van Waalwijk van Doorn-Khosrovani, P. N. Perrat, W. J. M. Van de Ven, R. Delwel, and L. H. Castilla Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11 Blood, April 1, 2005; 105(7): 2900 - 2907. [Abstract] [Full Text] [PDF] S. Buonamici, D. Li, F. M. Mikhail, A. Sassano, L. C. Platanias, O. Colamonici, J. Anastasi, and G. Nucifora EVI1 Abrogates Interferon-{alpha} Response by Selectively Blocking PML Induction J. Biol. Chem., January 7, 2005; 280(1): 428 - 436. [Abstract] [Full Text] [PDF] M. S. Tallman New Strategies for the Treatment of Acute Myeloid Leukemia Including Antibodies and Other Novel Agents Hematology, January 1, 2005; 2005(1): 143 - 150. [Abstract] [Full Text] [PDF] V. Biggio, S. Corm, H. Leroy, S. De Botton, C. Roumier, S. Depil, N. Philippe, J.-L. Lai, F. Bauters, P. Fenaux, et al. Poor Prognosis of Adult Acute Myeloid Leukemia (AML) with High Level of Evi1 and BAALC Transcript. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 2994 - 2994. [Abstract] A. H. Lund and M. van Lohuizen Epigenetics and cancer Genes & Dev., October 1, 2004; 18(19): 2315 - 2335. [Abstract] [Full Text] [PDF] P. Saussoy, J.-L. Vaerman, N. Straetmans, V. Deneys, G. Cornu, A. Ferrant, and D. Latinne Differentiation of Acute Myeloid Leukemia from B- and T-Lineage Acute Lymphoid Leukemias by Real-Time Quantitative Reverse Transcription-PCR of Lineage Marker mRNAs Clin. Chem., July 1, 2004; 50(7): 1165 - 1173. [Abstract] [Full Text] [PDF] P. J.M. Valk, R. G.W. Verhaak, M. A. Beijen, C. A.J. Erpelinck, S. B. v. W. van Doorn-Khosrovani, J. M. Boer, H. B. Beverloo, M. J. Moorhouse, P. J. van der Spek, B. Lowenberg, et al. Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia N. Engl. J. Med., April 15, 2004; 350(16): 1617 - 1628. [Abstract] [Full Text] [PDF] S. Frohling, R. F. Schlenk, I. Stolze, J. Bihlmayr, A. Benner, S. Kreitmeier, K. Tobis, H. Dohner, and K. Dohner CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations J. Clin. Oncol., February 15, 2004; 22(4): 624 - 633. [Abstract] [Full Text] [PDF] B. Lowenberg, J. D. Griffin, and M. S. Tallman Acute Myeloid Leukemia and Acute Promyelocytic Leukemia Hematology, January 1, 2003; 2003(1): 82 - 101. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020